Abstracts Archive - Page 1851 of 2425 - ACR Meeting Abstracts

Abstract Number: 2435 • 2015 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Adult Juvenile Idiopathic Arthritis Patients Treated with Biologic Agents
Katerina Jarosova¹, Katerina Andelova², Karel Hejduk³, Michal Uher³ and Jiri Vencovsky⁴, ¹Institute of Rheumatology, Prague, Czech Republic, ²clinical, Institute for the Care for Mother and Child, Prague, Czech Republic, ³Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, Charles University, Prague, Czech Republic
Background/Purpose: Biologic drugs are effective therapeutic option in patients with juvenile idiopathic arthritis (JIA). However, data regarding the use during pregnancy and breastfeeding in adult…
Abstract Number: 2436 • 2015 ACR/ARHP Annual Meeting
Views and Prescribing Habits of Pneumocystis Prophylaxis in the Pediatric Rheumatology Community
Matthew Basiaga¹, Alexis Ogdie-Beatty² and for the CARRA Investigators, ¹Pediatric Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ²Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Pneumocystis pneumonia (PCP) is a potentially devastating opportunistic infection. The incidence of PCP and the risk of adverse events secondary to prophylactic medication in…
Abstract Number: 2437 • 2015 ACR/ARHP Annual Meeting
Experience with Tocilizumab for Treatment of 56 Children with Systemic Juvenile Idiopathic Arthritis in the German JIA Biologics Register
Gerd Horneff¹, Gerd Ganser², Johannes Peter Haas³, Toni Hospach⁴, Ralf Trauzeddel⁵, Hans-Iko Huppertz⁶, J B. Kuemmerle-Deschner⁷, Kirsten Minden⁸ and BIKER Registry Study Group, ¹Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ²Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, ³German Centre for Rheumatology in Children and Young People, Garmisch-Partenkirchen, Germany, ⁴Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgard, Germany, ⁵HELIOS Klinikum Berlin-Buch Klinik fuer Kinder- und Jugendmedizin, Berlin, Germany, ⁶PRINTO, IRCCS G. Gaslini, Genoa, Italy, ⁷Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, ⁸DRFG, Berlin, Germany
Background/Purpose: Tocilizumab (TOC) has become a valuable option for treatment of systemic juvenile idiopathic arthritis (sJIA), which significantly improved the outcome of patients. The aim…
Abstract Number: 2438 • 2015 ACR/ARHP Annual Meeting
Clinical Examination of the Temporomandibular Joint; A Eurotmjoint Initiative
Bernd Koos¹, Peter Stoustrup², Lynn R. Spiegel³, Nikolay Tzaribachev⁴, Troels Herlin⁵, Thomas Klit Pedersen⁶ and Marinka Twilt⁷, ¹Orthodontics, University of Rostock, Rostock, Germany, ²Section of Orthodontics, University of Aarhus, Aarhus C, Denmark, ³Rheumatology/Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Pediatric Rheumatology, Center for Rheumatic Diseases, Bad Bramstedt, Germany, ⁵Department of Pediatrics, Århus University Hospital Skejby, Århus, Denmark, ⁶orthodontics, Aarhus University Hospital/Dental school, Aarhus, Denmark, ⁷Pediatric Rheumatology Clinic, Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Arthritis of the temporomandibular joint (TMJ) in patients with Juvenile Idiopathic Arthritis (JIA) is increasingly recognized. In the last decade, studies report that the…
Abstract Number: 2439 • 2015 ACR/ARHP Annual Meeting
Methotrexate Failure in Pediatric Uveitis
Courtney McCracken¹, Steven Yeh², Kirsten Jenkins³, Daneka Stryker⁴, Steven Tommasello⁵, Curtis Travers¹, Scott R. Lambert², Carolyn Drews-Botsch⁶ and Sheila T. Angeles-Han^1,2,3, ¹Pediatrics, Emory University School of Medicine, Atlanta, GA, ²Ophthalmology, Emory University School of Medicine, Atlanta, GA, ³Children's Healthcare of Atlanta, Atlanta, GA, ⁴Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, ⁵University of Alabama, Birmingham, AL, ⁶Epidemiology, Emory University School of Public Health, Atlanta, GA
Background/Purpose: Pediatric uveitis can lead to ocular complications and vision loss. Treatment consists of steroid drops, methotrexate (MTX), and anti-tumor necrosis factor (TNF) drugs. Only…
Abstract Number: 2440 • 2015 ACR/ARHP Annual Meeting
Using Patient-Relevant Variables to Describe the Disease Course in Children with Juvenile Idiopathic Arthritis
Jaime Guzman¹, Andrew Henrey², Thomas Loughin², Roberta Berard³, Natalie Shiff⁴, Roman Jurencak⁵, Susanne Benseler⁶, Lori B. Tucker⁷ and ReACCh-Out Investigators, ¹Rheumatology, Division of Rheumatology, BC Children's Hospital, Vancouver, BC, Canada, ²Statistics and Actuarial Science, Simon Fraser University, Burnaby, BC, Canada, ³Children's Hospital of Western Ontario, London, ON, Canada, ⁴Pediatric Rheumatology, University of Saskatchewan, Saskatoon, SK, Canada, ⁵University of Ottawa, Ottawa, ON, Canada, ⁶Alberta Children's Hospital Research Institute/University of Calgary, Calgary, AB, Canada, ⁷Rheumatology, BC Children's Hospital, Vancouver, BC, Canada
Background/Purpose: To define distinct disease course groups among children with Juvenile Idiopathic Arthritis (JIA) based on observed changes in quality of life, pain, medication requirements,…
Abstract Number: 2441 • 2015 ACR/ARHP Annual Meeting
Serum 14-3-3η Is Present in JIA and Is Not Associated with RF+ Polyarthritis
Alan M. Rosenberg¹, Walter Maksymowych², Yuan Gui³ and Anthony Marotta³, ¹Department of Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Augurex Life Sciences Corp., Vancouver, BC, Canada
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a collective term used to denote clinically discrete subtypes, which include: Enthesitis-related arthritis, Oligoarthritis, Polyarthritis, Psoriatic arthritis, Systemic arthritis…
Abstract Number: 2442 • 2015 ACR/ARHP Annual Meeting
The Family Journey to Diagnosis with Systemic Juvenile Idiopathic Arthritis As Evidenced through Changing Social Media Presence
Renee F Modica¹, Kathleen G Lomax², Pamela Batzel³, Leah Shapardanis³, Kimberly A Compton³ and Melissa E Elder⁴, ¹UF Health Shands Children’s Hospital, Gainesville, FL, ²Medical Affairs, Immunology and Dermatology, Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³TREATO, Princeton, NJ, ⁴Pediatrics, Univ of Florida, Gainesville, FL
Background/Purpose: Patients with systemic juvenile idiopathic arthritis (SJIA) frequently encounter delays from symptom onset to SJIA diagnosis (dx), partly due to the broad differential of…
Abstract Number: 2443 • 2015 ACR/ARHP Annual Meeting
Pediatric Tele-Rheumatology: A Pilot Project to Assess Accuracy of Physical Examination Findings and Diagnostic Concordance at a Distance
Michael Henrickson¹, Jody Raugh², Kelsey Hofacer³ and Adam Furnier⁴, ¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Occupational and Physical Therapy, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Center for Telehealth, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Quality Improvement Systems, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Telemedicine (TM) offers a strategic means of extending limited clinical pediatric rheumatology (PR) workforce capacity to improve access to care for patients in remote…
Abstract Number: 2444 • 2015 ACR/ARHP Annual Meeting
Accelerometer-Assessed Daily Physical Activity in Relation to Pain Cognitions and Quality of Life in Juvenile Idiopathic Arthritis
Mette Noergaard¹, Johanne Lomholt², Mikael Thastum², Morten Herlin³, Marinka Twilt⁴ and Troels Herlin⁴, ¹Department of Physiotherapy, Aarhus University Hospital, Aarhus, Denmark, ²Psychology and Social Sciences, Aarhus University, Aarhus, Denmark, ³Pediatrics, Aarhus University Hospital, Aarhus, Denmark, ⁴Pediatric Rheumatology Clinic, Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) has been associated with decreased physical activity (PA). However, accurate, objective measurements of PA related to potential factors limiting PA…
Abstract Number: L25 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Subcutaneous Tabalumab in Patients with Systemic Lupus Erythematosus (SLE): Results from 2 Phase 3, 52-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trials
David A. Isenberg¹, Murray B. Urowitz², Joan T. Merrill³, Robert W. Hoffman⁴, Matthew D. Linnik⁴, MaryAnn Morgan-Cox⁴, Melissa F. Veenhuizen⁴, Noriko Iikuni⁴, Michelle Petri⁵ and ILLUMINATE-1 Investigators, ¹University College London, London, United Kingdom, ²University of Toronto, Toronto Western Hospital, Toronto, ON, ³Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: B-cell Activating Factor (BAFF) is a key regulator of B-cell development, survival, and activation. Tabalumab is a human IgG4 monoclonal antibody, administered subcutaneously, that binds…
Abstract Number: 3017 • 2014 ACR/ARHP Annual Meeting
Program Evaluation of ‘the Joint Clinic’: An Innovative Clinical Service for Patients with Hip or Knee Osteoarthritis
J. Haxby Abbott¹, Helen Harcombe², Chris Crane³, Liam Hutton³, Kirsten Stout³, Cathy Chapple⁴ and David Gwynne-Jones⁵, ¹Centre for Musculoskeletal Outcomes Research, Department of Surgical Sciences, University of Otago, Dunedin, New Zealand, ²Centre for Musculoskeletal Outcomes Research, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand, ³Dunedin Hospital, Southern District Health Board, Dunedin, New Zealand, ⁴School of Physiotherapy, University of Otago, Dunedin, New Zealand, ⁵Orthopaedic Surgery, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand
Background/Purpose: In socialized healthcare systems with free public access to healthcare, there are circumstances wherein patients referred by general medical practitioners (GPs) for specialist physician…
Abstract Number: 3018 • 2014 ACR/ARHP Annual Meeting
Testing of a Newly Developed Computerized Animated Activity Questionnaire for Assessing Activity Limitations in Patients with Hip and Knee Osteoarthritis
Wilfred FH Peter¹, Mick Loos², Henrica de Vet³, Maarten Boers³, Jaap Harlaar⁴, Leo D. Roorda⁵, Rudolf Poolman⁶, Vanessa Scholtes⁶, Jan Bogaard⁷, Hilda Buitelaar¹, Martijn P.M. Steultjens⁸, Ewa M. Roos⁹, Anne-Christine Rat¹⁰, Francis Guillemin¹¹, Maria Grazia Benedetti¹², Antonio Escobar Martinez¹³, Nina Østerås¹⁴ and Caroline Terwee³, ¹Department of Epidemiology and Biostatistics, EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands, ²Epidemiology and Biostatistics and the EMGO Institute for Health and Care research, VU University Medical Center, Amsterdam, Netherlands, ³Dep of Epidemiology and Biostatistics, EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands, ⁴Dep of Rehabilitation Medicine and MOVE research institute, VU University Medical Center, Amsterdam, Netherlands, ⁵Amsterdam Rehabilitation Research Center | Reade, Amsterdam, the Netherlands, Amsterdam, Netherlands, ⁶Department of Orthopedics, Joint Research, Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands, ⁷Dep of Epidemiology and Biostatistics and the EMGO Institute for Health and Care research, VU University Medical Center, Amsterdam, Netherlands, ⁸Institute for Applied Health Research and School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, Scotland, ⁹Inst Sports and Biomechanics, University of Southern Denmark, Odense, Denmark, ¹⁰University Paris Descartes, EA 4360 APEMAC, University of Lorraine, Nancy, France, ¹¹INSERM, Centre d'Investigation Clinique - Epidémiologie Clinique (CIC-EC) CIE6, Nancy, France, ¹²Physical Medicine and Rehabilitation Unit, Istituto Ortopedico Rizzoli, Bologna, Italy, ¹³Health Service Research Network on Chronic Diseases (REDISSEC), Basurto University Hospital, Bilbao, Spain, ¹⁴Department of rheumatology, National Advisory Unit for rehabilitation in rheumatology, Diakonhjemmet Hospital, Oslo, Norway

Background/Purpose Self-report questionnaires and performance-based tests correlate moderately in measuring activity limitations, indicating that they measure different aspects. Self-reports measure mainly how patients think they…
Abstract Number: 2997 • 2014 ACR/ARHP Annual Meeting
Development and External Validation of a Five-Year Mortality Risk Stratification Tool for Early Diffuse Systemic Sclerosis Patients
Robyn T. Domsic¹, Svetlana I. Nihtyanova², Mary Lucas³, Stephen R. Wisniewski⁴, Michael J. Fine⁵, C. Kent Kwoh⁶, Christopher P. Denton⁷ and Thomas A. Medsger Jr.⁸, ¹Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Department of Rheumatology, Royal Free and University College Medical School, London, United Kingdom, ³Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ⁵General Medicine, University of Pittsburgh and Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare, Pittsburgh, PA, ⁶1501 N. Campbell Avenue, Room 8303, The University of Arizona Arthritis Center, Tucson, AZ, ⁷Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom, ⁸Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose : Knowledge of mortality risk and predictors is important in systemic sclerosis (SSc) patient care and clinical trial design. There is no validated 5-year…
Abstract Number: 2998 • 2014 ACR/ARHP Annual Meeting
Screening for Interstitial Lung Disease in Systemic Sclerosis: Performance of High-Resolution Computed Tomography with Limited Number of Slices – a Prospective Study
Thomas Frauenfelder¹, Anna Winklehner¹, Thi Dan Linh Nguyen¹, Rucsandra Dobrota^2,3, Stephan Baumüller¹, Britta Maurer² and Oliver Distler², ¹Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Zurich, Switzerland, ²Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ³Department of Internal Medicine and Rheumatology, Dr.I.Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Background/Purpose Early diagnosis of interstitial lung disease (ILD), currently the main cause of death in systemic sclerosis (SSc), is needed. The gold standard is high…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].